Patent ID: 6572860
Filing Date: 2003-06-03
Classification: A61K,A61P,C07K,C12N

Abstract:
An immunogenic conjugated polypeptide effective as immunogen in a vaccine for treatment or prevention of infection by herpes simplex virus, said polypeptide represented by the formula P1-x-P2 or P2-x-P1 where P1 represents a herpes simplex virus specific antigenic peptide from a protein of herpes simplex virus type 1 or type 2, selected from the group consisting of ICP27, glycoprotein B, ribonucleotide reductase, ICP4, ICP34.5, glycoprotein E and glycoprotein F; P2 represents an immunomodulatory peptide which is a portion of an immunoprotein which promotes binding to a class or subclass of T cells and which direct a predominantly TH1 type immune response to the peptide P1; and x represents a covalent bond or a cleavable or non-cleavable peptide linking group.